Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 15;19(1):693.
doi: 10.1186/s12885-019-5844-5.

Intra-arterial chemotherapy as primary or secondary treatment for infants diagnosed with advanced retinoblastoma before 3 months of age

Qiuying Chen  1   2 , Bin Zhang  1   2 , Yuhao Dong  3 , Xiaokai Mo  3 , Lu Zhang  3 , Jiejun Xia  4 , Jing Zhang  5 , Shuixing Zhang  6   7
Affiliations

Intra-arterial chemotherapy as primary or secondary treatment for infants diagnosed with advanced retinoblastoma before 3 months of age

Qiuying Chen et al. BMC Cancer. .

Abstract

Background: To evaluate the safety and efficacy of intra-arterial chemotherapy (IAC) for the primary or secondary treatment of infants diagnosed with advanced retinoblastoma before 3 months of age.

Methods: This single-center retrospective study included 39 infants (42 eyes) aged ≤3 months who were diagnosed with unilateral or bilateral advanced intraocular retinoblastoma (group D and E eyes) and received IAC as primary or secondary treatment between June 2012 and February 2017. Based on each patient's therapeutic history and response to chemotherapeutic drugs, melphalan, topotecan, and/or carboplatin were used for IAC. The main outcomes included the technical success rate for IAC, survival rates, and adverse events.

Results: In total, 29 and 13 eyes received IAC as primary and secondary treatments, respectively. Catheterization was successful in 136 of 137 procedures. All eyes in the secondary IAC group had previously received intravenous chemotherapy. The mean number of IAC sessions for each eye was 3 (range, 2-6). The 2-year ocular survival rates were 80.7% (95% confidence interval [CI], 58.9-91.7) in the primary IAC group and 91.7% (95% CI, 53.9-98.8) in the secondary IAC group. During the follow-up period, 1 patient with unilateral disease (group E) developed extraocular disease and died. The 2-year recurrence-free survival rates in the primary and secondary IAC groups were 71.9% (95% CI, 49.4-85.7) and 75.0% (95% CI, 40.8-91.2), respectively. During each catheterization procedure, the main complications included eyelid erythema (2.4%), fundus hemorrhage (11.9%), myelosuppression (7.7%), transient vomiting and hair loss (2.6%), and transient pancytopenia (2.6%). Prolonged complications included phthisis bulbi (19.0%), vision loss (19.0%), poor vision (9.5%), and cataract (2.4%). There was no case of stroke, neurological impairment, secondary malignant tumor, or metastasis.

Conclusions: Our findings suggest that IAC, whether primary or secondary, is effective and fairly safe for the management of advanced retinoblastoma in infants aged < 3 months. However, adverse events related to intra-arterial injection and the visual outcomes cannot be neglected and require further investigation.

Keywords: Advanced retinoblastoma; Complications; Infants; Intra-arterial chemotherapy; Survival outcomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Number of patients receiving different cycles of intra-arterial chemotherapy
Fig. 2
Fig. 2
Kaplan-Meier survival curves for IAC as primary or secondary treatment for patients diagnosed with advanced retinoblastoma under three months of age. Ocular survival (a), overall survival (b), and event-free survival (c). IVC = intravenous chemotherapy. IAC = intra-arterial chemotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203–212. doi: 10.1097/ICU.0b013e328338676a. - DOI - PubMed
    1. Wong JR, Tucker MA, Kleinerman RA, Devesa SS. Retinoblastoma incidence patterns in the US surveillance, epidemiology, and end results program. JAMA ophthalmology. 2014;132(4):478–483. doi: 10.1001/jamaophthalmol.2013.8001. - DOI - PubMed
    1. Abramson DH, Du TT, Beaverson KL. (Neonatal) retinoblastoma in the first month of life. Arch Ophthalmol. 2002;120(6):738–742. doi: 10.1001/archopht.120.6.738. - DOI - PubMed
    1. Abramson DH, Beaverson KL, Chang ST, Dunkel IJ, McCormick B. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004;122(9):1316–1323. doi: 10.1001/archopht.122.9.1316. - DOI - PubMed
    1. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma. Ophthalmology. 1998;105(4):573–580. doi: 10.1016/S0161-6420(98)94006-4. - DOI - PubMed

MeSH terms